MajorAtypical antipsychotic of the benzamide class×Prokinetic, dopamine D2 receptor antagonist
Updated · Methodology
Mechanism
Metoclopramide and amisulpride both block dopamine D2 receptors, and the Spanish metoclopramide summary of product characteristics (SmPC) places metoclopramide among neuroleptics (metoclopramide and amisulpride SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Their neuroleptic side effects therefore add up. The US Food and Drug Administration (FDA) metoclopramide label warns that with antipsychotics, tardive dyskinesia, other extrapyramidal symptoms and neuroleptic malignant syndrome may become more frequent and more severe (metoclopramide label, FDA). The Spanish metoclopramide SmPC notes an additive effect with other neuroleptics on extrapyramidal disorders (metoclopramide SmPC, AEMPS). Amisulpride itself prolongs the QT interval, more so at higher doses and concentrations (amisulpride SmPC, AEMPS; intravenous amisulpride label, FDA). Metoclopramide prolongs QT after injection, especially intravenous injection (metoclopramide SmPC, AEMPS). The documents give no data on either drug changing the blood levels of the other.
Symptoms
Both drugs cause extrapyramidal disorders on their own: tremor, stiffness and slowed movement, excess salivation, restlessness (akathisia) and acute muscle spasms with twisting of the neck, upward rolling of the eyes and jaw clenching (amisulpride and metoclopramide summaries of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). With metoclopramide they usually start early in treatment, sometimes after a single dose, and are more frequent in children and young adults and at high doses (metoclopramide SmPC, AEMPS). Long treatment with metoclopramide can cause tardive dyskinesia: involuntary movements of the face and tongue, sometimes of the trunk and limbs, that may be permanent (metoclopramide label, US Food and Drug Administration, FDA). Neuroleptic malignant syndrome causes high fever, muscle rigidity, altered consciousness, unstable pulse and blood pressure, sweating and raised creatine phosphokinase (amisulpride SmPC, AEMPS; metoclopramide label, FDA). QT prolongation shows only on the electrocardiogram. Torsade de pointes and ventricular tachycardia cause palpitations, dizziness and fainting and can end in cardiac arrest. After metoclopramide injection, severe bradycardia and circulatory collapse have also been reported (amisulpride and metoclopramide SmPCs, AEMPS).
Management
Avoid the combination (metoclopramide label, US Food and Drug Administration, FDA; amisulpride summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The FDA metoclopramide label says to avoid metoclopramide with antipsychotics because of the additive risk of tardive dyskinesia, other extrapyramidal symptoms and neuroleptic malignant syndrome. The Spanish amisulpride SmPC says to avoid concomitant neuroleptics, and the Spanish metoclopramide SmPC itself places metoclopramide among neuroleptics (amisulpride and metoclopramide SmPCs, AEMPS). Metoclopramide is contraindicated in people with earlier tardive dyskinesia caused by neuroleptics or metoclopramide (metoclopramide SmPC, AEMPS). If metoclopramide cannot be avoided, keep the course short: for adults no more than 30 mg a day, at least 6 hours between doses and no longer than 5 days (metoclopramide SmPC, AEMPS). Stop metoclopramide at the first extrapyramidal symptoms (metoclopramide SmPC, AEMPS). If neuroleptic malignant syndrome appears, stop metoclopramide and all antipsychotics, including amisulpride, at once and start treatment (metoclopramide and amisulpride SmPCs, AEMPS). Amisulpride prolongs the QT interval, so give metoclopramide with special care, especially intravenously, and inject intravenous doses slowly over at least 3 minutes (metoclopramide SmPC, AEMPS). For intravenous amisulpride as a single 5–10 mg dose, the FDA label recommends electrocardiogram monitoring in people taking other QT-prolonging drugs (intravenous amisulpride label, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reglan (metoclopramide) prescribing information (2026)– FDA, DailyMed setid de55c133-eb08-4a35-91a2-5dc093027397 (ANI Pharmaceuticals), revisión 02/2026 (versión 8), secciones 4, 5.1, 5.2, 5.3 y 7.1
- AEMPS: Ficha técnica: Amisulprida (nº registro 63996), sección 4.4 (2026)– AEMPS, CIMA, nº registro 63996 (Solian 400 mg), revisión 09/2026, secciones 4.3, 4.4, 4.5, 4.8 y 5.1
- AEMPS: Ficha técnica: Metoclopramida (nº registro 41446), sección 4.4 (2026)– AEMPS, CIMA, nº registro 41446 (Primperan 10 mg comprimidos), revisión 06/2026, secciones 4.2, 4.3, 4.4, 4.5 y 5.1
- FDA: Barhemsys (amisulpride) injection prescribing information (2026)– FDA, DailyMed setid ab23bc6e-b6a8-165f-e053-2a95a90ab144 (Acacia Pharma), revisión 06/2026 (versión 8), secciones 2.1, 5.1, 7.2 y 12.2; forma intravenosa en dosis única de 5–10 mg